Innovations in Cancer: Novel therapeutics, new diagnostics and future R&D strategies

SUMMARY

The cancer market is highly dynamic, creating a new age of discovery and innovation driven by molecular biology, oncogenomics and new methods in cell biology. These innovations will result in high value opportunities to develop newer and more effective therapies, ensuring companies can effectively respond to the increasing prevalence of cancer. 'Innovations in Cancer' provides a detailed insight into the evolution of the cancer market, the drivers and resistors of innovation and in-depth analysis of advances in both cancer therapeutics and diagnostics to provide a complete picture of how the cancer market will develop over the next five years. It also identifies key alliance and partnering opportunities highlighting companies with specialised capabilities in the discovery and the characterization of next-generation drug targets. Use this report to understand how the cancer market is developing, identify areas of unmet medical need and align your product pipeline to achieve clinical and commercial success.

TABLE OF CONTENTS

Executive Summary

• Current market landscape and dynamics
• Drivers and resistors of innovation
• Innovations in cancer therapeutics
• Innovations in cancer diagnostics
• New R&D strategies in cancer
• The future of the cancer market and conclusions

Chapter 1 Current market landscape and dynamics

• Summary
• Introduction
• Cancer epidemiology
• Sales by drug class
• Sales by brand
• Sales by company
• Sales by country
• Gold standard treatments
  • Lung cancer
  • Colorectal cancer
  • Breast cancer
  • Ovarian
  • Uterine
  • Leukemia
  • Prostate
  • Pancreatic
  • Lymphomas
• Unmet need
• Innovation in the cancer market
  • Targeted therapy
  • Cancer diagnostics

Chapter 2 Drivers and resistors of innovation

• Summary
• Introduction
• Drivers of innovation
  • Cancer statistics
  • Need
  • Risk
  • Scientific advances
  • Diagnostics
• Resistors
  • Market fragmentation
  • Reimbursement

Chapter 3 Innovations in cancer therapeutics

• Summary
• Introduction
• Key trends
• Key innovations
• Targeted therapies
• Cancer vaccines
• Small interfering RNAs
• Pipeline
• Addressing unmet need

Chapter 4 Innovations in cancer diagnostics

• Summary
• Introduction
• Cancer biomarkers
• Predicting cancer
• Diagnostic innovations by indication
  • Lung
  • Colon & rectum
  • Breast
  • Ovary
  • Uterus and cervix
  • Leukemia
  • Prostate
  • Pancreas
  • Lymphomas

Chapter 5 New R&D strategies in cancer

• Summary
• Introduction
• Background
• Oncogenomics
• Scientific approaches
• Small interfering RNA
• Biologicals
• Gene expression and biomarkers
• Arrays
• Drug delivery
• Cancer stem cells
• Looking ahead

Chapter 6 The future of the cancer market and conclusions

• Summary
• Introduction
• Key trends
• The future

Chapter 7 Appendix

• Index

List of Figures

• Figure 1.1: Incidence per cancer indication and country, 2005
• Figure 2.2: Drivers and resistors of innovation in the cancer market
• Figure 3.3: Companies developing new therapeutics for the "top four" cancers, 2007
• Figure 3.4: Numbers of drugs in development for the "top four" cancers, 2006
• Figure 3.5: Top companies developing therapeutics for the "top four" cancers, 2006
• Figure 3.6: Phase I-III pipeline for the "top four" cancers, 2006
• Figure 4.7: Categorization of cancer diagnostic tests
• Figure 4.8: Overview of diagnostics for 10 leading cancers, 2006

List of Tables

• Table 1.1: Incidence of 9 major tumor types in the 7 major markets, 2005
• Table 1.2: Global cancer market sales by drug class, 2004-05
• Table 1.3: Top 20 global cancer brands, 2004-05
• Table 1.4: Top 20 cancer companies by global sales, 2004-05
• Table 1.5: Global cancer market sales by drug class, 2004-05
• Table 1.6: Gold standard treatments and limitations
• Table 2.7: The World Cancer Report - 5 year survival rates
• Table 2.8: Incidence and prevalence for 9 cancers in 2005, for 7 major markets (US, Japan, France, Germany, Italy, Spain, UK)
• Table 2.9: Pipeline cancer drugs by indication, 2006
• Table 2.10: Data indicating unmet need in cancers based on the numbers of patients globally, 2002
• Table 3.11: Cancer vaccine pipeline, 2006
• Table 3.12: siRNA drug pipeline, 2006